Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

WCM/EADO 2021 | CMP-001 for PD-1 refractory patients with melanoma

Art Krieg, MD, Checkmate Pharmaceuticals, Cambridge, MA, outlines the potential of CMP-001 as an alternative therapy for patients who do not respond to PD-1 targeted checkpoint inhibitor therapy. CMP-001 is a virus-like particle that is a CpGA DNA toll-like receptor 9 agonist which triggers a strong T-cell response. This interview took place during the 10th World Congress of Melanoma in conjunction with the 17th EADO Congress Interactive Virtual Meeting.


Art Krieg, MD, is the Founder and CSO of Checkmate Pharmaceuticals.